• Renalytix entered partnership with Carna Health to integrate FDA-approved kidneyintelX.dkd with Carna digital care management platform to identify, stratify, and manage chronic kidney disease in US health systems.
• Collaboration targets earlier, risk-guided intervention for patients with type 2 diabetes and early-stage CKD, aiming to reduce disease progression and avoid high-cost dialysis starts.
• Renalytix cited clinical validation showing 72% relative improvement in identifying high-risk patients versus standard markers alone, with real-world data indicating high-risk patients were 4.5x more likely to receive SGLT2 inhibitors.
• Partnership framed as response to Medicare CKD spending of more than USD 130 billion annually, positioning combined offering for value-based care adoption.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Renalytix plc published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605120743PR_NEWS_USPR_____NY56627) on May 12, 2026, and is solely responsible for the information contained therein.